ClinicalTrials.gg
CompletedNCT04739865Updated Nov 9, 2023Results posted

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

A Phase 2 interventional study of Psilocybin in Treatment Resistant Depression, sponsored by COMPASS Pathways. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by COMPASS Pathways · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.

Enrollment
19th of 25
19 · median 30
Started
2020
the only one that year
Phase 2
18 of 25
8 open now
Registered
4th of 25
by date
Lead sponsor
4 of 25
COMPASS Pathways

Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 19th largest by enrollment, is the only one that started in 2020, is one of 18 in phase 2, and was the 4th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression

Read the detailed description

A recent open label study of the effects of psilocybin in participants with treatment-resistant depression (TRD) showed rapid significant decrease of depressive symptoms after treatment with psilocybin coupled with psychological support. Over 40% of participants sustained response at 3 months. In this study, the aim is to explore effectiveness of 25 mg of psilocybin as an adjunctive therapy in participants with TRD.

03

Conditions studied

  • Treatment Resistant Depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed ICF.
  2. 18 years of age or older
  3. At least moderate MDD
  4. Hamilton Depression Rating Scale (17 item) score ≥18
  5. Currently receiving treatment with a selective serotonin reuptake inhibitor
  6. Failure to respond to an adequate dose and duration of 2, 3, or 4 pharmacological treatments
  7. McLean Screening Instrument for Borderline Personality Disorder \<7 at Screening (V1).
  8. Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits.

Exclusion criteria

Exclusion Criteria:

Psychiatric Exclusion Criteria:

  1. Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, or borderline personality disorder, as assessed by medical history, McLean Screening Instrument for Borderline Personality Disorder and a structured clinical interview (version 7.0.2 MINI).
  2. Prior electroconvulsive therapy and/or ketamine for current episode.
  3. Ongoing use of an antidepressant medication, including augmentation or combination therapies, other than a single SSRI
  4. Current psychological therapies that will not remain stable within 21 days of the psilocybin session. Psychological therapies cannot be initiated within 21 days of baseline.
  5. Current (within the last year) alcohol or substance use disorder as informed by DSM 5 (diagnosed by MINI 7.0.2) at Screening (V1).
  6. Significant suicide risk as defined C-SSRS within the past year
  7. Depression secondary to other severe medical conditions according to clinicians' judgement.
  8. Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin, including exposure to psilocybin within the past year and use of psychedelics, such as ayahuasca, during the current depressive episode.

    General Medical Exclusion Criteria:

  9. Women who are pregnant, nursing or planning a pregnancy.
  10. Cardiovascular conditions
  11. Uncontrolled or insulin dependent diabetes.
  12. Seizure disorder.
  13. Positive urine drug screen for illicit drugs or drugs of abuse
  14. Current enrolment in any drug or device study or participation in such within 30 days prior to Screening (V1).
  15. Current enrolment in another clinical study of an investigational medical or participation in such within 30 days of Screening (V1).
  16. Abnormal and results on the physical examination, vital signs, or laboratory tests at Screening (V1).
  17. Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    25 mg COMP360 Psilocybin

    25 mg COMP360 Psilocybin

    Drug: Psilocybin

Interventions

06

What researchers measure

Primary outcomes

  1. Improvement in Depressive Symptoms

    Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to 3 weeks post psilocybin administration. The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.

    Time frame: 3 weeks

Secondary outcomes

  1. Incidence of Response

    The proportion of participants with a response (defined as a ≥ 50% improvement in Montgomery-Asberg Depression Rating Scale \[MADRS\] total score from Baseline) at Week 3 post psilocybin administration. The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.

    Time frame: 3 weeks

  2. Incidence of Remission

    The proportion of participants with remission (defined as Montgomery-Asberg Depression Rating Scale \[MADRS\] total score ≤ 10) at Week 3 post psilocybin administration The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.

    Time frame: 3 weeks

  3. Improvement in Clinical Global Impression - Severity

    Changes from Baseline in Clinical Global Impression-Severity score at Week 3 post psilocybin administration. The minimum and maximum values are 1 and 7 and a higher score means a worse outcome.

    Time frame: 3 weeks

07

Results

Posted Nov 9, 2023

Participant flow

First patient first visit: 10 August 2020 Last patient last visit: 13 October 2021

Participant flow — Overall Study
Milestone25 mg COMP360 Psilocybin
Started19
Completed19
Not completed0

Outcome measures

PrimaryImprovement in Depressive Symptoms

Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to 3 weeks post psilocybin administration. The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.

Time frame:
3 weeks
Reported as:
Mean · units on a scale
Improvement in Depressive Symptoms
units on a scale25 mg COMP360 Psilocybin
Improvement in Depressive Symptoms-14.9 ± 11.97
SecondaryIncidence of Response

The proportion of participants with a response (defined as a ≥ 50% improvement in Montgomery-Asberg Depression Rating Scale \[MADRS\] total score from Baseline) at Week 3 post psilocybin administration. The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.

Time frame:
3 weeks
Reported as:
Count of participants · Participants
Incidence of Response
Participants25 mg COMP360 Psilocybin
Incidence of Response8
SecondaryIncidence of Remission

The proportion of participants with remission (defined as Montgomery-Asberg Depression Rating Scale \[MADRS\] total score ≤ 10) at Week 3 post psilocybin administration The minimum and maximum MADRS total score values are 0 and 60 and a higher score means a worse outcome.

Time frame:
3 weeks
Reported as:
Count of participants · Participants
Incidence of Remission
Participants25 mg COMP360 Psilocybin
Incidence of Remission8
SecondaryImprovement in Clinical Global Impression - Severity

Changes from Baseline in Clinical Global Impression-Severity score at Week 3 post psilocybin administration. The minimum and maximum values are 1 and 7 and a higher score means a worse outcome.

Time frame:
3 weeks
Reported as:
Mean · units on a scale
Improvement in Clinical Global Impression - Severity
units on a scale25 mg COMP360 Psilocybin
Improvement in Clinical Global Impression - Severity-1.3 ± 1.29

Adverse events

Collected over Up to 3 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
25 mg COMP360 Psilocybin0/19 (0%)0/19 (0%)12/19 (63.2%)
Most frequent other events
Most frequent other events
Event25 mg COMP360 Psilocybin
HeadacheNervous system disorders6/19
Blood Pressure IncreasedInvestigations3/19
PalpitationsCardiac disorders1/19
VertigoEar and labyrinth disorders1/19
DiarrhoeaGastrointestinal disorders1/19
Dry MouthGastrointestinal disorders1/19
FallInjury, poisoning and procedural complications1/19
Skin AbrasionInjury, poisoning and procedural complications1/19
DizzinessNervous system disorders1/19
DepressionPsychiatric disorders1/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Psilocybin
<=18 years4
Between 18 and 65 years15
>=65 years0
Age, Continuous
Age, Continuous(years)Psilocybin
Mean42.2 ± 10.80
Sex: Female, Male
Sex: Female, Male(Participants)Psilocybin
Female13
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Psilocybin
Hispanic or Latino0
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Psilocybin
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White15
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)Psilocybin
United States9
Ireland10
08

Study locations

2 sites
  • Kadima Neuropsychiatry Institute
    La Jolla, California 92037, United States
  • Sheaf House, Tallaght Hospital
    Dublin, Ireland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2021, 14 months.

Results were first posted in Nov 2023, 2 years after primary completion.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2020
First posted
Feb 5, 2021
StartActual
Aug 10, 2020
Primary completionActual
Oct 14, 2021
CompletionActual
Oct 14, 2021
Results first posted
Nov 9, 2023
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04739865
Lead sponsor
COMPASS Pathways
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Aug 10, 2020
Primary completion
Oct 14, 2021
Completion
Oct 14, 2021
Results posted
Nov 9, 2023
Last update
Nov 9, 2023

Study contacts

Guy Goodwin
principal investigator · University of Oxford

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion